{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:57:33Z","timestamp":1791910653712,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Roche \/ Genentech"],"award-info":[{"award-number":["Roche \/ Genentech"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001127","name":"Genentech Foundation","doi-asserted-by":"publisher","award":["Genentech \/ Roche"],"award-info":[{"award-number":["Genentech \/ Roche"]}],"id":[{"id":"10.13039\/100001127","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011957","name":"Takeda Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.cllc.2019.05.006","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T21:24:13Z","timestamp":1557523453000},"page":"339-349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Computed Tomography Imaging Characteristics of Non\u2013Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"20","author":[{"given":"Dexter P.","family":"Mendoza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Stowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Muzikansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Anne O.","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subba R.","family":"Digumarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2019.05.006_bib1","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2019.05.006_bib2","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non\u2013small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2019.05.006_bib3","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2019.05.006_bib4","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.cllc.2019.05.006_bib5","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.21037\/jtd.2017.08.134","article-title":"Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment na\u00efve advanced lung adenocarcinoma","volume":"9","author":"Miao","year":"2017","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.cllc.2019.05.006_bib6","first-page":"12782","article-title":"The diagnostic and follow-up role of radiological examination in advanced lung adenocarcinoma with anaplastic lymphoma kinase gene rearrangement","volume":"10","author":"Zhang","year":"2017","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.cllc.2019.05.006_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00330-015-3814-0","article-title":"CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non\u2013small-cell lung cancer","volume":"26","author":"Rizzo","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cllc.2019.05.006_bib8","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.ejrad.2016.08.023","article-title":"Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations","volume":"85","author":"Wang","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cllc.2019.05.006_bib9","doi-asserted-by":"crossref","first-page":"e0161081","DOI":"10.1371\/journal.pone.0161081","article-title":"Imaging characteristics of driver mutations in EGFR, KRAS, and ALK among treatment-na\u00efve patients with advanced lung adenocarcinoma","volume":"11","author":"Park","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2019.05.006_bib10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.athoracsur.2015.07.062","article-title":"Radiologic characteristics of surgically resected non\u2013small-cell lung cancer with ALK rearrangement or EGFR mutations","volume":"101","author":"Kim","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cllc.2019.05.006_bib11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1148\/radiol.14140848","article-title":"Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation","volume":"275","author":"Choi","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.cllc.2019.05.006_bib12","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1097\/RLU.0000000000000581","article-title":"Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma","volume":"40","author":"Jeong","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cllc.2019.05.006_bib13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00330-014-3516-z","article-title":"Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations","volume":"25","author":"Zhou","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cllc.2019.05.006_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5761\/atcs.oa.14-00093","article-title":"Imaging characteristics in ALK fusion-positive lung adenocarcinomas by using HRCT","volume":"21","author":"Nakada","year":"2015","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2019.05.006_bib15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.lungcan.2014.09.007","article-title":"Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?","volume":"86","author":"Halpenny","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.05.006_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1148\/radiol.14140789","article-title":"ALK molecular phenotype in non\u2013small-cell lung cancer: CT radiogenomic characterization","volume":"272","author":"Yamamoto","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.cllc.2019.05.006_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.cllc.2019.05.006_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cllc.2019.05.006_bib19","series-title":"Review Manager (RevMan) Version 5.3","year":"2014"},{"key":"10.1016\/j.cllc.2019.05.006_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cllc.2019.05.006_bib21","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1158\/1078-0432.CCR-10-0851","article-title":"Optimizing the detection of lung cancer\u00a0patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment","volume":"16","author":"Camidge","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2019.05.006_bib22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2019.05.006_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.lungcan.2012.03.013","article-title":"Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene","volume":"77","author":"Fukui","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.05.006_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.lungcan.2011.11.008","article-title":"Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma","volume":"76","author":"Paik","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.05.006_bib25","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2019.05.006_bib26","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cllc.2019.05.006_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12880-016-0175-3","article-title":"CT characteristics of non\u2013small-cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis","volume":"17","author":"Cheng","year":"2017","journal-title":"BMC Med Imaging"},{"key":"10.1016\/j.cllc.2019.05.006_bib28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10147-019-01403-3","article-title":"CT and clinical characteristics that predict risk of EGFR mutation in non\u2013small-cell lung cancer: a systematic review and meta-analysis","volume":"24","author":"Zhang","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib29","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/0284186X.2017.1328128","article-title":"Miliary metastases are associated with epidermal growth factor receptor mutations in non\u2013small-cell lung cancer: a population-based study","volume":"56","author":"Hsu","year":"2017","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.cllc.2019.05.006_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JTO.0b013e3181fb7cf1","article-title":"Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion","volume":"6","author":"Laack","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10555-015-9592-y","article-title":"Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?","volume":"34","author":"Toyokawa","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.cllc.2019.05.006_bib32","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non\u2013small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2019.05.006_bib33","doi-asserted-by":"crossref","first-page":"1119-28","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non\u2013small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib34","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1002\/cncr.27409","article-title":"Oncogene status predicts patterns of metastatic spread in treatment-naive non\u2013small-cell lung cancer","volume":"118","author":"Doebele","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2019.05.006_bib35","first-page":"2017","article-title":"Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non\u2013small-cell lung cancer","author":"Gainor","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib36","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1634\/theoncologist.2016-0179","article-title":"Screening for ALK rearrangements in lung cancer: time for a new generation of diagnostics?","volume":"21","author":"Dagogo-Jack","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2019.05.006_bib37","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non\u2013small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jtho.2015.12.111","article-title":"ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm","volume":"11","author":"Marchetti","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib39","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/annonc\/mdt295","article-title":"Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma","volume":"24","author":"Ying","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib40","doi-asserted-by":"crossref","first-page":"82943","DOI":"10.18632\/oncotarget.12705","article-title":"ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma","volume":"7","author":"Dacic","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2019.05.006_bib41","doi-asserted-by":"crossref","first-page":"12510","DOI":"10.1038\/s41598-017-12679-8","article-title":"Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches","volume":"7","author":"Vendrell","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2019.05.006_bib42","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced non\u2013small-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2011.10.017","article-title":"The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group","volume":"76","author":"Thunnissen","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.05.006_bib44","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1200\/JOP.2016.014019","article-title":"Impact of reflex EGFR\/ALK testing on time to treatment of patients with advanced nonsquamous non\u2013small-cell lung cancer","volume":"13","author":"Cheema","year":"2016","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.cllc.2019.05.006_bib45","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/j.cllc.2017.03.001","article-title":"Molecular testing turnaround time for non\u2013small-cell lung cancer in routine clinical practice confirms feasibility of CAP\/IASLC\/AMP guideline recommendations: a single-center analysis","volume":"18","author":"DiStasio","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2019.05.006_bib46","first-page":"2018","article-title":"Clinical utility of rapid EGFR genotyping in advanced lung cancer","author":"Dagogo-Jack","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib47","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1097\/JTO.0000000000000467","article-title":"BIRC6-ALK, a novel fusion gene in ALK break-apart FISH-negative lung adenocarcinoma, responds to crizotinib","volume":"10","author":"Shan","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib48","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/JTO.0b013e3182614ab5","article-title":"Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non\u2013small-cell lung cancer","volume":"7","author":"Peled","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib49","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/JTO.0000000000000013","article-title":"Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non\u2013small-cell lung cancer","volume":"9","author":"Ren","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib50","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1097\/JTO.0b013e318274694e","article-title":"A\u00a0dramatic response to crizotinib in a non\u2013small-cell lung cancer patient with IHC-positive and FISH-negative ALK","volume":"7","author":"Sun","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.05.006_bib51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jtho.2016.08.145","article-title":"Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment","volume":"12","author":"Li","year":"2017","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041930110X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041930110X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:08:55Z","timestamp":1761505735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573041930110X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S152573041930110X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2019.05.006","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computed Tomography Imaging Characteristics of Non\u2013Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2019.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}